Compare LEDS & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | NCEL |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | Taiwan | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 12.0M |
| IPO Year | 2010 | N/A |
| Metric | LEDS | NCEL |
|---|---|---|
| Price | $1.58 | $2.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.7K | ★ 186.8K |
| Earning Date | 01-14-2026 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 824.43 | N/A |
| 52 Week Low | $1.41 | $1.89 |
| 52 Week High | $3.37 | $7.64 |
| Indicator | LEDS | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 49.64 |
| Support Level | $1.51 | $2.40 |
| Resistance Level | $1.79 | $2.86 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 15.68 | 38.55 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.